Parkinson's Disease Trial, Recruiting NCT06570824 Sponsor: Danish Research Centre for Magnetic Resonance Condition: Parkinson's Disease
Back to Parkinsons Disease

Parkinson's Disease Trial, Recruiting

NCT06570824
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been clinically diagnosed with established or probable Parkinson's disease, based on recognised diagnostic criteria
  • People who experience involuntary movements (such as wriggling or writhing) at the point when their levodopa medication is working at its strongest (known as peak-of-dose dyskinesia)
  • People whose Parkinson's medications have remained unchanged for at least four weeks
  • People who are willing and able to give signed consent to participate

Who may not be able to join:

  • People who have a psychiatric disorder
  • People who are currently taking antipsychotic medication, Donepezil, or certain nerve-calming medications such as pregabalin or gabapentin
  • People who regularly use benzodiazepines or opioid medications more than once per week
  • People who have a history of a neurological condition other than Parkinson's disease
  • People who have a personal history of epilepsy or any condition that may increase the risk of seizures triggered by a brain stimulation technique called TMS
  • People who have close relatives with epilepsy or conditions that may increase the risk of seizures triggered by TMS
  • People who have any medical reason they cannot have an MRI scan
  • Female participants of childbearing age who are pregnant, or who are not willing to use contraception during the trial
  • People who do not wish to be informed about any new or incidental health-related findings that may arise during their participation in the study

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 6 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Hartwig R. Siebner, Prof., Head of Research, Prof, DMSc

Phone: +45 38621184

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Danish Research Centre for Magnetic Resonance
Registry
ClinicalTrials.gov
Start date
22 July 2024
Est. completion
1 May 2027

Where this trial is recruiting

🇩🇰 Denmark

Primary endpoints

Unified Dyskinesia Rating Scale (UDysRS); Dyskinesia onset time

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 6 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov